Objective: Validate cGAS-STING pathway activation as a mechanistically significant driver of dopaminergic neurodegeneration in PD and test therapeutic targeting with cGAS/STING inhibitors.
Hypothesis: Chronic cGAS-STING activation in microglia and neurons driven by cytosolic DNA accumulation (primarily mitochondrial DNA) triggers type I interferon responses that accelerate alpha-synuclein aggregation and drive progressive dopaminergic neuron loss. Pharmacological inhibition will attenuate neurodegeneration and improve functional outcomes.
A. In vitro: iPSC-Derived Models
| Parameter |
Details |
| Model |
iPSC-derived microglia + dopaminergic neurons from PD patients (LRRK2 G2019S, idiopathic, GBA carriers) and healthy controls |
| Condition Groups |
Control, PD neurons only, PD neurons + cGAS activators (dsDNA transfection), PD neurons + cGAS-STING inhibitors (G150, H151) |
| Readouts |
- cGAS, STING, p-STING expression (Western blot, immunofluorescence) - cGAMP production (mass spectrometry) - IFN-β, ISG expression (qPCR, ELISA) - α-synuclein aggregation (pSer129) - Neuronal survival (MAP2+ counts, TUNEL) - Mitochondrial function ( Seahorse) |
B. In vivo: Mouse Models
| Parameter |
Details |
| Models |
MPTP-induced PD model, α-synuclein pre-formed fibril (PFF) model, PINK1 knockout (mtDNA release model) |
| Treatment Groups |
Vehicle, cGAS inhibitor (G150, 30mg/kg i.p. daily), STING inhibitor (H151, 10mg/kg i.p. daily), Positive control (L-DOPA) |
| Duration |
4 weeks post-MPTP, 8 weeks post-PFF injection |
| Readouts |
- Behavioral: cylinder test, stepping test, gait analysis, rotarod - Biochemical: striatal dopamine, TH+ neuron counts in SNc - Molecular: cGAS-STING pathway activation (cGAMP, p-STING) - Type I IFN markers: IFN-β, ISG56 - Inflammation: Iba1+ microglial density, cytokine levels - α-synuclein pathology: pSer129 burden |
A. Biomarker Discovery
| Parameter |
Details |
| Cohort |
120 PD patients (de novo, early-stage), 60 healthy controls |
| Samples |
CSF, plasma, peripheral blood mononuclear cells (PBMCs) |
| Biomarkers |
cGAMP (CSF and plasma), STING, p-STING, IFN-β, ISG56, CXCL10 in CSF; genetic variants in cGAS/STING genes |
| Correlation |
UPDRS motor score, MoCA, DAT-SPECT imaging, disease progression rate |
B. Clinical Validation
| Parameter |
Details |
| Design |
Cross-sectional, multi-center |
| Cohort |
400 PD patients (various stages), 150 controls |
| Primary Endpoint |
Biomarker levels vs. clinical measures |
| Secondary |
Biomarker changes over 24-month follow-up |
A. Study Design
| Parameter |
Details |
| Design |
Randomized, double-blind, placebo-controlled |
| Population |
Early-stage PD (Hoehn & Yahr 1-2) with elevated cGAMP or IFN markers |
| Intervention |
STING inhibitor (to be determined based on BBB penetration) or placebo |
| Duration |
52 weeks |
| Sample Size |
80 patients (40 per arm) |
| Primary Endpoints |
- Change in UPDRS Part III (motor) - Change in CSF cGAMP and IFN-β |
| Secondary Endpoints |
- DAT-SPECT progression - MoCA cognitive scores - Quality of life (PDQ-39) - Biomarker response |
flowchart TD
A["Phase 1: Preclinical"] --> B["iPSC Validation"]
A --> C["Animal Models"]
B --> D{"Validates cGAS-STING Hypothesis?"}
C --> D
D -->|"Yes"| E["Phase 2: Biomarker Development"]
D -->|"No"| F["Modify Hypothesis"]
E --> G["Biomarker Validation"]
G --> H["Phase 3: Clinical Trial"]
H --> I["FDA Approval Pathway"]
style A fill:#e1f5fe
style E fill:#e1f5fe
style H fill:#e1f5fe
- cGAS-STING Activation: Significant increase in cGAS, p-STING, cGAMP in PD models vs. controls
- Type I IFN Response: Elevated IFN-β and ISG expression in PD neurons and mouse brain
- Neuroprotection: cGAS-STING inhibitor treatment reduces neuron loss by ≥35%
- α-Synuclein Modulation: Reduced pSer129 aggregation with inhibitor treatment
- Biomarker Correlation: CSF cGAMP levels correlate with motor severity (r ≥ 0.4)
- Treatment Effect: STING inhibitor reduces IFN biomarkers by ≥25% vs. baseline
- Effect Size: 35% reduction in neuron loss with treatment
- α: 0.05
- Power: 0.80
- n per group: 15 mice
- Expected correlation: r = 0.4
- α: 0.05
- Power: 0.80
- n: 120 PD patients
- Expected difference: 4 points UPDRS Part III
- SD: 10 points
- α: 0.05, two-sided
- Power: 0.80
- n: 40 per arm (accounting for 20% dropout)
- Animal Use: 3R principles (replacement, reduction, refinement)
- Human Subjects: IRB approval, informed consent, data safety monitoring board
- Risk Mitigation: Use STING inhibitors with established safety profiles
| Phase |
Duration |
Milestone |
| Phase 1A (iPSC) |
9 months |
Validated in vitro model |
| Phase 1B (animal) |
15 months |
Preclinical proof-of-concept |
| Phase 2 |
18 months |
Biomarker validation complete |
| Phase 3 |
36 months |
Phase I/II trial complete |
| Phase |
Cost (USD) |
| Phase 1 |
$1.8M |
| Phase 2 |
$1.2M |
| Phase 3 |
$6.5M |
| Total |
$9.5M |
| Risk |
Likelihood |
Mitigation |
| Inadequate BBB penetration of inhibitors |
High |
Prioritize BBB-penetrant STING inhibitors; prodrug strategies |
| Pathway not central in PD |
Moderate |
Comprehensive mechanistic studies; patient stratification |
| Off-target effects |
Low |
Selective inhibitors; careful safety monitoring |
| Biomarker assay development needed |
Moderate |
Develop CSF cGAMP assay with pharma partners |
| Patient recruitment |
Moderate |
Multi-center design; patient advocacy groups |
- Mechanistic Validation: cGAS-STING activation confirmed as significant contributor to PD neurodegeneration
- Biomarker Utility: cGAMP validated as PD progression marker
- Therapeutic Efficacy: STING inhibitor shows acceptable safety and preliminary efficacy